Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a... Am J Cardiovasc Drugs (2018) 18:143–151 https://doi.org/10.1007/s40256-018-0264-5 SHORT COMMUNICATION Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic 1 1 Elizabeth K. Pogge Lindsay E. Davis Published online: 17 February 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract blood pressure of 6 mmHg with no significant changes in Objective The objective of this research was to describe serum creatinine, blood urea nitrogen, or potassium levels. the use of pharmacist-managed sacubitril/valsartan therapy Conclusions With close monitoring and follow-up, ARNi in a multi-center, outpatient cardiac group. therapy was a safe alternative to ACEi/ARB therapy for Background Sacubitril/valsartan, an angiotensin receptor- chronic symptomatic HFrEF when initiated within a neprilysin inhibitor (ARNi), is a novel agent for the treat- pharmacist clinic. ment of heart failure. An ARNi is recommended by national guidelines to be used in place of angiotensin- Abbreviations ACEi Angiotensin-converting enzyme converting enzyme inhibitor (ACEi) or angiotensin recep- tor blocker (ARB) therapy for patients who remain inhibitor AHA American Heart Association symptomatic. Methods A retrospective chart review was performed to ARB Angiotensin receptor blocker identify patients initiated and fully titrated on sacubi- ARNi Angiotensin receptor-neprilysin tril/valsartan therapy from July 7, 2015 to March http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic

Loading next page...
 
/lp/springer_journal/evaluating-the-safety-and-tolerability-of-sacubitril-valsartan-for-xa7s2j8gcf
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
D.O.I.
10.1007/s40256-018-0264-5
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2018) 18:143–151 https://doi.org/10.1007/s40256-018-0264-5 SHORT COMMUNICATION Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic 1 1 Elizabeth K. Pogge Lindsay E. Davis Published online: 17 February 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract blood pressure of 6 mmHg with no significant changes in Objective The objective of this research was to describe serum creatinine, blood urea nitrogen, or potassium levels. the use of pharmacist-managed sacubitril/valsartan therapy Conclusions With close monitoring and follow-up, ARNi in a multi-center, outpatient cardiac group. therapy was a safe alternative to ACEi/ARB therapy for Background Sacubitril/valsartan, an angiotensin receptor- chronic symptomatic HFrEF when initiated within a neprilysin inhibitor (ARNi), is a novel agent for the treat- pharmacist clinic. ment of heart failure. An ARNi is recommended by national guidelines to be used in place of angiotensin- Abbreviations ACEi Angiotensin-converting enzyme converting enzyme inhibitor (ACEi) or angiotensin recep- tor blocker (ARB) therapy for patients who remain inhibitor AHA American Heart Association symptomatic. Methods A retrospective chart review was performed to ARB Angiotensin receptor blocker identify patients initiated and fully titrated on sacubi- ARNi Angiotensin receptor-neprilysin tril/valsartan therapy from July 7, 2015 to March

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Feb 17, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off